Toyoda Y, Di Gregorio V, Parker R A, Levitsky S, McCully J D
Division of Cardiothoracic Surgery and Biometrics Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02115, USA.
Circulation. 2000 Nov 7;102(19 Suppl 3):III326-31. doi: 10.1161/01.cir.102.suppl_3.iii-326.
Adenosine-enhanced ischemic preconditioning (APC) extends the protection afforded by ischemic preconditioning (IPC) by both significantly decreasing infarct size and significantly enhancing post-ischemic functional recovery. In this study, the anti-infarct effects and the anti-stunning effects of APC in contributing to enhanced post-ischemic functional recovery were determined and compared with IPC.
Sheep (n=96) were subjected to 15, 30, 45, or 60 minutes of regional ischemia and 120 minutes of reperfusion. IPC hearts received 5 minutes of regional ischemia and 5 minutes of reperfusion before ischemia/reperfusion. APC hearts received a bolus injection of adenosine coincident with IPC. Adenosine hearts (ADO) received a bolus injection of adenosine before ischemia/reperfusion. Regional ischemia (RI) hearts received no pretreatment. Infarct size/area at risk was determined by tetrazolium staining. Regional myocardial function was determined by sonomicrometry. Segment shortening after 15 minutes of ischemia in which no infarct was incurred was 32. 1+/-10.6% in RI, 70.6+/-8.5% in IPC, and 77.4+/-6.0% in APC hearts. Segment shortening after 30 minutes of ischemia was 60.7+/-6.3% in APC hearts (P:<0.05 versus RI, ADO, IPC) but was <37% in all other groups. Infarct size/area at risk after 30 and 60 minutes of ischemia was, respectively, 25.8+/-5.7% and 49.8+/-6.0% in RI, 12. 9+/-3.0% and 29.2+/-5.0% in ADO, 11.6+/-2.4% and 24.6+/-2.7% in IPC, and 5.1+/-1.6% and 12.4+/-2.0% in APC hearts (P:<0.05 versus RI, ADO, IPC).
APC and IPC exhibit anti-infarct and anti-stunning effects in the ovine heart, but these effects are rapidly diminished with IPC. APC significantly extends these effects, providing for significantly enhanced infarct size reduction and post-ischemic functional recovery (P:<0.05 versus IPC).
腺苷增强的缺血预处理(APC)通过显著减小梗死面积和显著增强缺血后功能恢复,扩展了缺血预处理(IPC)所提供的保护作用。在本研究中,确定了APC在促进缺血后功能恢复方面的抗梗死作用和抗顿抑作用,并与IPC进行了比较。
96只绵羊接受15、30、45或60分钟的局部缺血和120分钟的再灌注。IPC组心脏在缺血/再灌注前接受5分钟的局部缺血和5分钟的再灌注。APC组心脏在IPC时同时接受一次腺苷推注。腺苷组(ADO)在缺血/再灌注前接受一次腺苷推注。局部缺血(RI)组心脏未接受预处理。通过四氮唑染色确定梗死面积/危险面积。通过超声心动图测定局部心肌功能。在未发生梗死的情况下,缺血15分钟后的节段缩短率在RI组为32.1±10.6%,在IPC组为70.6±8.5%,在APC组为77.4±6.0%。缺血30分钟后,APC组心脏的节段缩短率为60.7±6.3%(与RI、ADO、IPC组相比,P<0.05),而其他所有组均<37%。缺血30分钟和60分钟后的梗死面积/危险面积在RI组分别为25.8±5.7%和49.8±6.0%,在ADO组为12.9±3.0%和29.2±5.0%,在IPC组为11.6±2.4%和24.6±2.7%,在APC组为5.1±1.6%和12.4±2.0%(与RI、ADO、IPC组相比,P<0.05)。
APC和IPC在绵羊心脏中均表现出抗梗死和抗顿抑作用,但这些作用在IPC时会迅速减弱。APC显著扩展了这些作用,使梗死面积显著减小,缺血后功能恢复显著增强(与IPC组相比,P<0.05)。